CIPLA vs DRREDDY: Stock Comparison
Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a higher ROE, a higher dividend yield and faster revenue growth, while Dr Reddys Laboratories Ltd shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CIPLA leads 11; DRREDDY leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CIPLA | DRREDDY |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | CIPLA | DRREDDY |
|---|---|---|
| Live Price | ₹1,430.3 | ₹1,185.2 |
| Day Change | -0.08% | -0.57% |
| Volume | 2.09 L | 3.94 L |
| 52-Week High | ₹1,673 | ₹1,414.9 |
| 52-Week Low | ₹1,165.7 | ₹1,101 |
| Distance from 52W High | -14.51% | -16.23% |
Valuation
| Metric | CIPLA | DRREDDY |
|---|---|---|
| Market Cap | ₹1.16 L Cr | ₹98,959 Cr |
| P/E Ratio | 34.27x | 30.87x |
| P/B Ratio | 3.35x | 2.63x |
| EPS | ₹41.76 | ₹39.72 |
| Book Value | ₹426.25 | ₹460.31 |
| Dividend Yield | 0.9% | 0.67% |
Growth
| Metric | CIPLA | DRREDDY |
|---|---|---|
| Revenue Growth (TTM YoY) | -2.1% | -11.6% |
| EPS Growth (TTM YoY) | -54.6% | -86.2% |
| Qtr Sales Growth | -2.8% | -11.5% |
| Qtr Profit Growth | -54.6% | -86.1% |
Profitability & Leverage
| Metric | CIPLA | DRREDDY |
|---|---|---|
| ROE | 11.6% | 11.2% |
| ROCE | 15.5% | 13% |
| Net Margin | 13.96% | 12.76% |
| Operating Margin | 20.9% | 19.2% |
| Debt to Equity | 0.02x | 0.2x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CIPLA | DRREDDY |
|---|---|---|
| Promoter Holding | 9.17% | 26.64%▲ 0.01 pp |
| FII Holding | 20.21%▼ 2.35 pp | 32.07%▼ 1.01 pp |
| DII Holding | 34.63%▲ 2.66 pp | 31.74%▲ 1.02 pp |
| Public Holding | 15.94%▼ 0.31 pp | 9.35%▲ 0.02 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Dr Reddys Laboratories Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.